# National Institute for Health and Care Excellence

# Early and locally advanced breast cancer: diagnosis and management Neoadjuvant and OFS update

NICE guideline: acknowledgments

NICE guideline NG101 Authors and contributors February 2025

> Commissioned by the National Institute for Health and Care Excellence

Early and locally advanced breast cancer: diagnosis and management: Neoadjuvant and OFS update

#### Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their careful or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <u>Welsh Government</u>, <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>. All NICE guidance is subject to regular review and may be updated or withdrawn.

#### Copyright

© NICE 2025. All rights reserved. Subject to Notice of rights.

Early and locally advanced breast cancer: diagnosis and management: Neoadjuvant and OFS update

# Contents

1

Guid	uideline developers		
1.1	Members of the NICE guideline committee	. 5	
1.2	Members of the NICE Guideline Development Team	5	
1.3	Members of the wider NICE Team	. 5	

Early and locally advanced breast cancer: diagnosis and management: Neoadjuvant and OFS update

## **1** Guideline developers

## **1.1 Members of the NICE guideline committee:**

Name	Role
Adam Firth	Committee Chair
Ramsey Cutress	Topic Adviser – Breast Surgeon
Mark Davies	Medical oncologist
Kay Davies-Crowley	Nurse specialist
Milly Finch	Pharmacist
Rachael Griffin	Lay member
Sadaf Haque	GP
Kwok Leung Cheung	Breast surgeon
Tim Robinson	Medical oncologist
Elinor Sawyer	Clinical oncologist
David Talbot	Lay member
Katy Tan	Lay member
Ben Thwaites	Pharmacist

### **1.2 Members of the NICE Guideline Development Team:**

Name	Role
Sarah Boyce	Senior Technical Analyst
Lindsay Claxton	Health Economics Adviser
Marie Harrisingh	Topic Lead
Adam O'Keefe	Project Manager
Hannah Tebbs	Senior Health Economist
Alfredo Mariani	Senior Health Economist
Yolanda Martinez	Technical Analyst

### **1.3 Members of the wider NICE Team:**

Name	Role
Jeremy Braybrooke	Consultant Clinical Adviser
Chris Carmona	Technical Adviser (QA)
Victoria Carter	Implementation Support Manager
Gareth Haman	Senior Guidance Content Designer
Andrea Heath	Senior Information Specialist
Lesley Owen	Health Economics Adviser (QA)
Katherine Saxby	Medicines Advisor
Sarah Scott	Public Involvement Adviser
Adam Storrow	Business Analyst - Resource Impact